ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-SLITRK6 Antibody-drug Conjugate GEN1106

Its studies are mostly in Carcinoma, Transitional Cell, led by Genmab.

Furthest: phase 1, since Feb 10, 20261 company-led study, 1 open or runningNext primary completion: Apr 5, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab11 open or runningphase 1since Feb 10, 2026Feb 10, 2026Apr 5, 2029phase 1 · NCT07416123

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2026First study: phase 1 study in Carcinoma, Transitional CellFirst studyNCT07416123 · 103 planned · United States, Japan, Spain

Ahead

  1. Apr 5, 2029Primary completion: phase 1 study in Carcinoma, Transitional CellNCT07416123

TargetBeta

SLITRK6 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07416123Carcinoma, Transitional Cell · United States, Japan, Spain1RecruitingApr 5, 2029103

How it is read

Names in the registry

  • “GEN1106”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.